4 stories found
Bloomberg reports that AstraZeneca, Sanofi, and Boehringer Ingelheim are investing in Owkin's AI platform to overcome bottlenecks in pharmaceutical research and rapidly generate drug candidates.
AI biotech firm Owkin has signed a collaborative agreement with pharmaceutical giant Boehringer Ingelheim to leverage machine learning for accelerating drug discovery in oncology and immunology.
Biotech company Owkin has signed a strategic agreement with pharmaceutical giant Boehringer Ingelheim to leverage artificial intelligence for accelerating the development of treatments targeting cancer and immunological diseases.
Boehringer Ingelheim has partnered with artificial intelligence firm Owkin to accelerate drug discovery efforts focused on cancer and immunology. The collaboration marks another major industry move as pharmaceutical companies increasingly integrate machine learning into early-stage research.